GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Degree of Operating Leverage

NVAX (Novavax) Degree of Operating Leverage : -4.41 (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Novavax Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Novavax's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -4.41. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Novavax's Degree of Operating Leverage or its related term are showing as below:

NVAX's Degree of Operating Leverage is ranked better than
87.17% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs NVAX: -4.41

Novavax Degree of Operating Leverage Historical Data

The historical data trend for Novavax's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Degree of Operating Leverage Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.78 0.41 -0.08 0.28 43.20

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.41 1.26 -3.10 43.20 -4.41

Competitive Comparison of Novavax's Degree of Operating Leverage

For the Biotechnology subindustry, Novavax's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Novavax's Degree of Operating Leverage falls into.


;
;

Novavax Degree of Operating Leverage Calculation

Novavax's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 510.206 (Mar. 2025) / -381.386 (Mar. 2024) - 1 )/( 1214.641 (Mar. 2025) / 793.744 (Mar. 2024) - 1 )
=-2.3378/0.5303
=-4.41***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Novavax  (NAS:NVAX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Novavax Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Novavax's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax Business Description

Industry
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Executives
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100